METABOLIC · Oral
5-Amino 1MQ.
NNMT inhibitor for metabolic activation
How it works
Class & mechanism.
Class
NNMT Inhibitor (Small Molecule)
Mechanism
5-Amino-1MQ (5-amino-1-methylquinolinium) is a cell-membrane-permeable small molecule that selectively inhibits nicotinamide N-methyltransferase (NNMT) — an enzyme overexpressed in white adipose tissue under obese/high-fat conditions that converts nicotinamide to N-methylnicotinamide, consuming methyl groups and depleting intracellular NAD+. By blocking NNMT with an IC50 of ~1 µM without affecting other methyltransferases or cytochrome P450 enzymes, 5-Amino-1MQ preserves the nicotinamide pool for NAD+ synthesis, raising intracellular NAD+ levels 1.2–1.6 fold in adipocytes. Elevated NAD+ activates sirtuin deacetylases (particularly SIRT1 and SIRT3) and AMPK pathways, which shift adipocytes from a fat-storing to a fat-burning metabolic state, inhibit adipogenesis-related transcription factors (PPARγ, C/EBPα, SREBP1), and increase mitochondrial fatty acid oxidation and energy expenditure.
Did you know
Unlike every other weight-loss compound, 5-Amino-1MQ achieves fat cell shrinkage of 30–40% without any change in appetite, food intake, or hormone levels — purely by removing a metabolic 'brake' (the NNMT enzyme) that obese fat cells use to hoard energy. It breaks the vicious cycle where excess fat literally produces more of the enzyme that makes it harder to lose fat.
Benefits
What it does.
Fat cell shrinkage without caloric restriction — adipocyte size reduced by 30–40% and volume by over 40% in obese animal models
Visceral and subcutaneous white fat reduction — targeting the most metabolically dangerous fat depots
Increased NAD+ levels (1.2–1.6x) activating anti-aging sirtuins (SIRT1/SIRT3) and improving mitochondrial efficiency
Total cholesterol reduction ~30% and normalized lipid profiles in treated animals
Lipogenesis (new fat formation) inhibited by up to 70% in adipocytes from treated subjects
Muscle function and recovery enhancement — 2024 study showed additive grip strength improvements with exercise in aged mice
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
Neelakantan et al. (2017/2018): Mice given 5-Amino-1MQ (20 mg/kg SC, 3×/day) for 11 days lost 5.1% body weight while controls gained 1.4%, with >30% reduction in adipocyte size, >40% reduction in adipocyte volume, and ~30% lower total cholesterol — no change in food intake
SOURCE · Biochemical Pharmacology / Scientific Reports, Neelakantan et al., 2017; PMC5826726
Kraus et al. (Nature Medicine): NNMT inhibition in white adipose tissue increased energy expenditure and reduced fat mass in animal models without altering food intake or physical activity, confirming the metabolic re-wiring mechanism
SOURCE · Nature Medicine, Kraus et al.
Waterson et al. (2022): NNMT inhibition combined with calorie restriction established a distinct gut microbiome profile in diet-induced obese mice, suggesting additional metabolic and immune benefits beyond direct fat metabolism
SOURCE · Nature Communications, Waterson et al., 2022
Dimet-Wiley et al. (2024, Scientific Reports): NNMT inhibition with 5-Amino-1MQ mimicked and additively boosted exercise-mediated improvements in muscle function in aged mice, with unique proteomic signatures suggesting applications in sarcopenia
SOURCE · Scientific Reports, Dimet-Wiley et al., 2024 (PMID: 38969654)
Protocol
How to use it.
Dosing
Research compound only — no approved human dosing. Preclinical animal protocol: 20 mg/kg subcutaneous, 3×/day for 11 days. Practitioner-adapted human protocols typically use 50 mg oral capsules, 1–2× daily (50–100 mg/day total). Standard starting dose: 50 mg/day for tolerance assessment, titrating to 100 mg/day if well-tolerated. Oral capsule form — no injection required.
Cycle
Typical research/wellness cycle: 4–6 weeks on, followed by 2–4 week break. Avoid dosing close to bedtime as NAD+ elevation may affect circadian signaling. Not FDA-approved; classified as a research chemical. No human clinical trials registered or completed as of 2024. All efficacy data from rodent models.
Contraindications
When to skip it.
No formal human safety data. No FDA approval or clinical trial data in humans. Preclinical animal studies showed favorable safety profile with no adverse hepatic effects at efficacy doses. Highly selective for NNMT vs other methyltransferases, reducing theoretical off-target risk. Use with caution in patients on medications affecting NAD+ metabolism (e.g., niacin, NMN). Not recommended during pregnancy or breastfeeding. Consult a healthcare provider before use.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for 5-Amino 1MQ, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Oral capsules — no needles required
- 03Concierge supplier match included with every protocol
See 5-Amino 1MQ pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $189–$283 USD